Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMUR2 | Q9GZQ4 | 3/20 | 0.58 |
| ▸ | NMUR1 | Q9HB89 | 3/20 | 0.58 |
| ▸ | APLNR | P35414 | 1/20 | 0.57 |
| ▸ | NPY2R | P49146 | 5/20 | 0.57 |
| ▸ | NPY4R | P50391 | 5/20 | 0.57 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.57 |
| ▸ | NPY1R | P25929 | 4/20 | 0.57 |
| ▸ | RAMP3 | O60896 | 1/20 | 0.57 |
| ▸ | CALCR | P30988 | 1/20 | 0.57 |
| ▸ | TFPI | P10646 | 4/20 | 0.57 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.56 |
| ▸ | GLP1R | P43220 | 3/20 | 0.56 |
| ▸ | GCGR | P47871 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31303098 | 0.92 | NMUR2 (0.62) | NMUR2NMUR1APLNRNPY2RNPY4R | |
| SCHEMBL30842169 | 0.88 | NMUR2 (0.65) | NMUR2NMUR1APLNRTFPI | |
| SCHEMBL29586781 | 0.88 | OPRM1 (0.57) | NMUR2NMUR1APLNRRAMP3CALCR | |
| SCHEMBL30842159 | 0.88 | NMUR2 (0.64) | NMUR2NMUR1APLNRTFPICXCR4 | |
| SCHEMBL30432935 | 0.88 | NMUR2 (0.61) | NMUR2NMUR1NPY2RNPY4RNPY5R | |
| SCHEMBL30495655 | 0.88 | NMUR2 (0.64) | NMUR2NMUR1NPY2RNPY4RNPY5R | |
| SCHEMBL29697076 | 0.87 | NMUR2 (0.62) | NMUR2NMUR1RAMP3CALCRTFPI | |
| SCHEMBL31183013 | 0.87 | NPY2R (0.64) | NPY2RNPY4RNPY5RNPY1RRAMP3 | |
| SCHEMBL29410232 | 0.86 | KEAP1 (0.67) | NMUR2NMUR1NPY2RNPY4RNPY5R | |
| SCHEMBL31121841 | 0.86 | NMUR2 (0.68) | NMUR2NMUR1NPY2RNPY4RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4642475-A2 | ARTIFICIAL SECRETION PEPTIDES FOR HETEROLOGOUS PROTEIN PRODUCTION | Tenza, Inc. (US) | 2025-11-05 | — | — | EP | claimed |
| US-20250221968-A1 | TREATMENTS AND METHODS FOR INCREASING DOPAMINE | UNIV OXFORD INNOVATION LTD (GB) | 2025-07-10 | — | — | US | claimed |
| EP-4493171-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONIST/BLOCKER FOR USE IN INCREASING DOPAMINE | Zhang, Yanfeng C/o Oxford University Innovation Limited (GB) | 2025-01-22 | — | — | EP | claimed |
| WO-2024145571-A2 | ARTIFICIAL SECRETION PEPTIDES FOR HETEROLOGOUS PROTEIN PRODUCTION | TENZA, INC. (US) | 2024-07-04 | — | — | WO | claimed |
| WO-2023175357-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONIST/BLOCKER FOR USE IN INCREASING DOPAMINE | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2023-09-21 | — | — | WO | claimed |
| US-12631654-B2 | Non-invasive assay for detecting and monitoring systemic inflammation | ICHILOV TECH LTD. (IL) | 2026-05-19 | — | — | US | disclosed |
| CN-117024411-B | Isoquinoline as HPK1 inhibitor | 豪夫迈·罗氏有限公司 | 2026-05-19 | — | — | CN | disclosed |
| WO-2026096690-A1 | COMPOSITIONS AND METHODS TO TREAT NEURODEGENERATION AND COGNITIVE DECLINE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-07 | — | — | WO | disclosed |
| WO-2026095932-A1 | COMPOSITIONS AND METHODS TO TREAT NEURODEGENERATION AND COGNITIVE DECLINE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-07 | — | — | WO | disclosed |
| EP-4642475-A2 | ARTIFICIAL SECRETION PEPTIDES FOR HETEROLOGOUS PROTEIN PRODUCTION | Tenza, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| US-20250327816-A1 | BIOMARKERS FOR THE PREDICTION OF PRETERM BIRTH | UNIVERSITé LAVAL (CA) | 2025-10-23 | — | — | US | disclosed |
| EP-3732489-B1 | NOVEL BIOMARKERS AND METHODS FOR DIAGNOSING AND EVALUATING TRAUMATIC BRAIN INJURY | ABBOTT LAB (US) | 2025-10-22 | — | — | EP | disclosed |
| CN-217033966-U | Kit for combined detection of catastatin and NT-proBNP in sample | 北京大学第三医院（北京大学第三临床医学院） | 2022-07-22 | — | — | CN | disclosed |
| CN-217033966-U | Kit for combined detection of catastatin and NT-proBNP in sample | 北京大学第三医院（北京大学第三临床医学院） | 2022-07-22 | — | — | CN | disclosed |
| CN-217033966-U | Kit for combined detection of catastatin and NT-proBNP in sample | 北京大学第三医院（北京大学第三临床医学院） | 2022-07-22 | — | — | CN | disclosed |
| CN-217033965-U | Kit for combined detection of catastatin, BNP and NT-proBNP in sample | 北京大学第三医院（北京大学第三临床医学院） | 2022-07-22 | — | — | CN | disclosed |
| US-20220211914-A1 | HYALURONIC ACID HYDROGELS WITH PROLONGED ANTIMICROBIAL ACTIVITY | SPARTHA MEDICAL (FR) | 2022-07-07 | — | — | US | disclosed |
| US-20220213461-A1 | ASX-SPECIFIC PROTEIN LIGASES AND USES THEREOF | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2022-07-07 | — | — | US | disclosed |
| EP-3966321-A1 | ASX-SPECIFIC PROTEIN LIGASES AND USES THEREOF | Nanyang Technological University (SG) | 2022-03-16 | — | — | EP | disclosed |
| EP-3962543-A1 | HYALURONIC ACID HYDROGELS WITH PROLONGED ANTIMICROBIAL ACTIVITY | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2022-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12631654-B2 | Non-invasive assay for detecting and monitoring systemic inflammation | CXCL10, MIF, CXCL8 | NMUR2 348/4885NMUR1 781/4885APLNR 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.